(8S,13S,14S,17S)-5,10,17-Trihydroxy-13-methyl-17-prop-1-ynyl-1,2,4,5,6,7,8,10,12,13,14,15,16,17-tetradeca hydro-cyclopenta[a]phenanthren-3-one


Product Details

CAT No.# CS-O-16564
Category Impurities
Molecular Weight 344.44
Molecular Formula C21H28O4
Purity: >98
Synonyms: (8S,13S,14S,17S)-5,10,17-trihydroxy-13-methyl-17-(prop-1-yn-1-yl)-4,5,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one
Application Notes: Impurity in commercial preparations of Mifepristone.
COA / MSDS:    View COA    MSDS    Enquire
The balance used are calibrated with weights traceable to National Standards NIST for accuracy
Related Results for '(8S,13S,14S,17S)-5,10,17-Trihydroxy-13-methyl-17-prop-1-ynyl-1,2,4,5,6,7,8,10,12,13,14,15,16,17-tetradeca hydro-cyclopenta[a]phenanthren-3-one'

- API Standards of Mifepristone
- Stable Isotopes of Mifepristone
- Metabolites of Mifepristone
- Impurities of Mifepristone
- Glucuronides of Mifepristone
- Intermediates of Mifepristone

PEOPLE ALSO SEARCHED FOR: 1. (6R,7S)-7-(2-chloroacetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
2. 3-bromo-2,2-dimethyl-butane
3. propan-2-yl-5-hydroxy-2-methyl-2-4-(3-nitrophenyl)-6-oxo-1,4,5,5-tetraahydropyridine-3-carboxylate
4. ([13C6]Leu5)-Ghrelin (human) (H-7252.1000)
5. Benidipine D7
6. Lauroside D
7. Triazolam 13C D3
8. Icatibant impurity 1
10. 0.1% TFA in Water ULC-MS
11. Metamizole EP Impurity C HCl
12. Silodosin Metabolite D4
13. Brivaracetam Carboxylic acid metabolite [UCB 42145]
14. Terbuthylazine D5
15. tibolone (848)
16. (Z)-Dimethylvinphos
17. Silodosin Metabolite
18. 2-Phenoxymethanesulfonanilide
19. Nimesulide EP Impurity A
20. Acetone HPLC

This page contains information about (8S,13S,14S,17S)-5,10,17-Trihydroxy-13-methyl-17-prop-1-ynyl-1,2,4,5,6,7,8,10,12,13,14,15,16,17-tetradeca hydro-cyclopenta[a]phenanthren-3-one Cas NA and its Impurities.
"Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk."